ACURA PHARMACEUTICALS, INC Form 8-K November 03, 2006

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act Of 1934

November 3, 2006

Date of Report (Date of earliest event reported)

ACURA PHARMACEUTICALS, INC.

(Exact Name of Registrant as Specified in Charter)

State of New York

1-10113

11-0853640

(State of Other Jurisdiction (Commission File Number) of Incorporation)

(I.R.S. Employer Identification Number)

616 N. North Court, Suite 120 Palatine, Illinois 60067

(Address of principal executive offices) (Zip Code)

(847) 705-7709

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d- 2(b))
- o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17CFR 240.13e-4(c))

Edgar Filing: ACURA PHARMACEUTICALS, INC - Form 8-K

Item 2.02 Results of Operations and Financial Condition

On November 3, 2006, Acura Pharmaceuticals, Inc. (the "Company") issued a press release disclosing the financial results for its third quarter ended September 30, 2006. A copy of the Company's press release is attached as Exhibit 99.1 hereto.

Item 9.01 Financial Statements and Exhibits

Exhibit Number	Description
99.1	Press Release dated November 3, 2006 Announcing Financial Results for Third Quarter 2006
2	

Edgar Filing: ACURA PHARMACEUTICALS, INC - Form 8-K

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

ACURA PHARMACEUTICALS, INC.

By: /s/ Peter A. Clemens

Peter A. Clemens
Senior Vice President & Chief Financial Officer

Date: November 3, 2006

3

Edgar Filing: ACURA PHARMACEUTICALS, INC - Form 8-K

Exhibit Index

Exhibit Number	Description
99.1	Press Release dated November 3, 2006 Announcing Financial Results for Third Quarter 2006
4	